Last $1.62 USD
Change Today +0.07 / 4.52%
Volume 163.1K
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

soligenix inc (SNGX) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/14 - $2.49
52 Week Low
12/19/14 - $0.91
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SOLIGENIX INC (SNGX)

Related News

No related news articles were found.

soligenix inc (SNGX) Related Businessweek News

No Related Businessweek News Found

soligenix inc (SNGX) Details

Soligenix, Inc., a clinical stage biopharmaceutical company, is engaged in developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and various biodefense vaccines and therapeutics. The company operates in, BioTherapeutics and Vaccine/Biodefense. The BioTherapeutics segment develops proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn’s disease, acute radiation enteritis, and chronic graft-versus-host disease, as well as novel innate defense regulator technology for the treatment of oral mucositis. The Vaccines/BioDefense segment offers RiVax, a ricin toxin vaccine; VeloThrax, an anthrax vaccine; OrbeShield, a gastrointestinal acute radiation syndrome program; and SGX943, a melioidosis therapeutic. These vaccine programs are supported by the company’s heat stabilization technology, known as ThermoVax. The company has collaboration with Intrexon Corporation to focus on the joint development of a treatment for Melioidosis, a high priority biothreat and an area of unmet medical need. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was founded in 1987 and is headquartered in Princeton, New Jersey.

17 Employees
Last Reported Date: 12/19/14
Founded in 1987

soligenix inc (SNGX) Top Compensated Officers

Chairman, Chief Execdutive Officer and Presid...
Total Annual Compensation: $641.0K
Acting Chief Financial Officer, Vice Presiden...
Total Annual Compensation: $276.0K
Compensation as of Fiscal Year 2013.

soligenix inc (SNGX) Key Developments

Soligenix, Inc. Presents Data from its Recent Preclinical Study of Ricin Toxin Vaccine

Soligenix, Inc. announced that it presented data from its recent preclinical study that demonstrated the efficacy and safety of its heat-stabilized ricin toxin vaccine (RiVax) in a non-human primate (NHP) lethal aerosolized ricin exposure model. The data was presented in a poster session at the American Society of Microbiology (ASM) Biodefense and Emerging Diseases Research meeting on February 11, 2015 at Washington Marriott Wardman Park, 2660 Woodley Rd. NW in Washington, DC. Soligenix has been developing RiVax, its proprietary ricin toxin vaccine, in conjunction with its heat stabilization technology, ThermoVax, as a heat-stable biodefense vaccine. Vaccination with RiVax protected all animals from acute lethal death due to aerosolized ricin exposure, in contrast to unvaccinated animals that died within 40 hours. In the study, 12 animals were vaccinated with RiVax and 6 animals were given an injection of placebo (unvaccinated control). Each animal received 3 intramuscular injections, administered at time 0, 30 days and 60 days. Vaccination with RiVax was well tolerated with no evidence of elevated heart rate, respiration or temperature. All RiVax-vaccinated animals generated neutralizing antibodies after the third injection. To fully test the efficacy of the vaccine, all animals were exposed to an aerosol of ricin toxin 3-5 times the amount that is known to result in death of untreated animals. All RiVax-vaccinated animals survived exposure, while all unvaccinated control animals died within 40 hours, demonstrating a statistically significant (p<0.0001) improvement in survival. Moreover, the lungs of the RiVax™-vaccinated animals did not demonstrate any signs of irreversible damage, unlike those of the unvaccinated control animals.

Soligenix, Inc. Announces Publication of Data Demonstrating Enhanced Immunogenicity and Rapid Action of its Anthrax Vaccine, VeloThrax

Soligenix, Inc. announced the publication of data demonstrating enhanced immunogenicity and rapid action of its anthrax vaccine, VeloThrax. VeloThrax employs a derivative of recombinant protective antigen, termed Dominant Negative Inhibitor (DNI), which is a candidate for inclusion in a next generation anthrax vaccine. The use of the Company's proprietary vaccine stabilization technology, ThermoVax, has been previously demonstrated to enhance the thermostability of VeloThrax, enabling distribution without cold chain requirements. In this work, the use of two adjuvants, aluminum hydroxide and Glycopyranoside Lipid A (GLA) in conjunction with ThermoVax, was demonstrated to further enhance the immunogenicity and rapid action of the vaccine. The recent development of a VeloThrax formulation containing both aluminum hydroxide and GLA has resulted in immune responses indicative of protection after no more than 2 administrations of the vaccine in a shortened (less than one month) vaccination regimen, in an animal model. These results are indicative of a vaccine that can be given to humans in an abbreviated regimen, compared to the currently available vaccine. Next generation anthrax vaccines have been targeting a shortened vaccination schedule with fewer vaccinations for both pre and post-exposure use. Previous studies have also demonstrated the potential ability to combine the VeloThrax vaccine with Soligenix's RiVax (ricin toxin) vaccine. These studies were performed under the aegis of a $9.4 million cooperative grant from the National Institute of Allergy and Infectious Diseases (NIAID) for the development of the ThermoVax technology.  The work was conducted by collaborators at the University of Colorado (including Drs. John Carpenter and Ted Randolph), the Wadsworth Center, New York State Department of Health (including Drs. Nicolas J. Mantis and David Vance) and by the University of Kansas (including Drs. Russ Middaugh and David Volkin).

Soligenix, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015

Soligenix, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 . Venue: Westin St. Francis Hotel, San Francisco, California, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNGX:US $1.62 USD +0.07

SNGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SNGX.
View Industry Companies

Industry Analysis


Industry Average

Valuation SNGX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SOLIGENIX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at